Exscientia plc (EXAI) |
5.3 0 (0%)
|
03-31 16:00 |
Open: |
5.28 |
Pre. Close: |
5.3 |
High:
|
5.43 |
Low:
|
5.25 |
Volume:
|
200,437 |
Market Cap:
|
654(M) |
|
|
Technical analysis |
as of: 2023-03-31 4:18:32 PM |
Overall:
|
|
Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
Target: |
Six months: 7.43 One year: 8.36 |
Support: |
Support1: 5.07 Support2: 4.21 |
Resistance: |
Resistance1: 6.36 Resistance2: 7.15 |
Pivot: |
6.18  |
Moving Average: |
MA(5): 5.44 MA(20): 6.28 
MA(100): 6.32 MA(250): 8.73  |
MACD: |
MACD(12,26): -0.4 Signal(9): -0.3  |
Stochastic oscillator: |
%K(14,3): 16.9 %D(3): 17.5  |
RSI: |
RSI(14): 39.4 |
52-week: |
High: 16.45 Low: 4.09 |
Average Vol(K): |
3-Month: 299 (K) 10-Days: 350 (K) |
|
Price, moving averages and Bollinger Bands |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ EXAI ] has closed above bottom band by 12.4%. Bollinger Bands are 4.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
Stock Price Prediction |
Update at 5:00pm EST |
If tomorrow:
|
Open lower
|
Open higher
|
High:
|
5.74 - 5.77 |
5.77 - 5.8 |
Low:
|
5.06 - 5.1 |
5.1 - 5.13 |
Close:
|
5.24 - 5.3 |
5.3 - 5.35 |
|
Company Description |
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom. |
Headline News |
Thu, 23 Mar 2023 Exscientia Business and Financial Update for the Full Year 2022 - Business Wire
Thu, 16 Mar 2023 Exscientia to Report Full Year 2022 Financial Results on March 23 ... - Tullahoma News and Guardian
Thu, 16 Mar 2023 Short Volatility Alert: Exscientia Plc - Exscientia (NASDAQ:EXAI) - Benzinga
Wed, 15 Mar 2023 Exscientia to Present Data Highlighting Pipeline and Precision ... - Business Wire
Sat, 11 Mar 2023 Exscientia plc's (NASDAQ:EXAI) market cap dropped US$65m last week; individual investors who hold 57% were hit as were institutions - Simply Wall St
Tue, 07 Mar 2023 Exscientia Announces Collaboration with Charité to Advance ... - Business Wire
|
Financial Analysis |
Price to Book Value: |
Outperform |
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Price to Earnings: |
Underperform |
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Discounted cash flow: |
Outperform |
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Return on Assets: |
Neutral |
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Return on Equity: |
Neutral |
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Debt to Equity: |
Neutral |
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
Free Technical Analysis Charts
|
|
Stock Basics & Statistics |
Exchange: NASDAQ |
Sector: Healthcare |
Industry: Biotechnology |
Shares Out. |
123 (M) |
Shares Float |
104 (M) |
% Held by Insiders
|
16.2 (%) |
% Held by Institutions
|
28.7 (%) |
Shares Short
|
2,290 (K) |
Shares Short P.Month
|
1,870 (K) |
Stock Financials |
EPS
|
-1.56 |
EPS Est Next Qtl
|
0 |
EPS Est This Year
|
0 |
EPS Est Next Year
|
0 |
Book Value (p.s.)
|
4.15 |
Profit Margin (%)
|
0 |
Operating Margin (%)
|
-585.7 |
Return on Assets (ttm)
|
-18.4 |
Return on Equity (ttm)
|
-26.8 |
Qtrly Rev. Growth
|
-64.4 |
Gross Profit (p.s.)
|
0.08 |
Sales Per Share
|
0.19 |
EBITDA (p.s.)
|
-1.12 |
Qtrly Earnings Growth
|
0 |
Operating Cash Flow
|
-28 (M) |
Levered Free Cash Flow
|
-58 (M) |
Stock Valuations |
PE Ratio
|
-3.4 |
PEG Ratio
|
0 |
Price to Book value
|
1.27 |
Price to Sales
|
26.52 |
Price to Cash Flow
|
-23.56 |
Stock Dividends |
Dividend
|
0 |
Forward Dividend
|
0 |
Dividend Yield
|
0% |
Dividend Pay Date
|
Invalid DateTime. |
Ex-Dividend Date
|
Invalid DateTime. |
Your Ad Here
|
|